Vutrisiran · AMVUTTRA

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
EU
  • Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)investors.alnylam.com
  • Hereditary transthyretin-mediated amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathyEMA
Product first approved 2022
JP
  • TTR type familial amyloidosis with polyneuropathy
investors.alnylam.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Transthyretin Amyloidosis with Cardiomyopathy
NCT06679946 · Alnylam Pharmaceuticals
2024-12-03 – 2028-03-31 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
What this study did
Other / comorbidity
Phase 1 (1)
Other / comorbidity
NCT02797847 · Alnylam Pharmaceuticals
2016-06-07 – 2018-01-12 · Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Transthyretin Amyloidosis with Polyneuropathy
NCT07223203 · Alnylam Pharmaceuticals
2026-02-03 – 2031-06-12 · Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Polyneuropathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vutrisiran (AMVUTTRA): this drugApprovedRNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT03759379: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43)
Eplontersen (Wainua)ApprovedRNA / oligonucleotideTransthyretin (TTR)Weak signalNo reviewed efficacy summary in this indication
Patisiran (ONPATTRO)ApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT01960348: Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602)
Inotersen (Tegsedi)US approval withdrawnRNA / oligonucleotideTransthyretin (TTR)Reliable signalNo reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow AMVUTTRA (Vutrisiran) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
March 2028 (1)
Phase 3Transthyretin Amyloidosis with CardiomyopathyEnrolling by invitation
Est. primary completion 2028-03-31 · NCT06679946 · CT.gov ↗
What to watch

See the full readout calendar ↗